22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › FATE THERAPEUTICS INC. › 2024-2025

FATE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and FATE THERAPEUTICS INC.’s Form 8-K, filed May 30, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 9Reported items
  • 144Asset managers, any item
  • 1,569Fund votes
  • May 29, 2025Meeting date

Results at a glance

Meeting of May 29, 2025: 8 items on FATE THERAPEUTICS INC.’s Form 8-K, filed May 30, 2025: 3 elected · 5 passed (calculated).

Dissent

Notable dissent: 2 other board items (24.8%, 17.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore FATE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by FATE THERAPEUTICS INC.

These tallies are FATE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 30, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

FATE THERAPEUTICS INC. — official shareholder meeting results, meeting held May 29, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Shefali Agarwal 65,856,345---- 2,690,58819,634,302 96%Elected—
Elect Director: Bahram Valamehr, Ph.D., M.B.A. 67,859,201---- 687,73219,634,302 99%Elected—
Elect Director: Matthew C. Abernethy, M.B.A. 67,935,382---- 611,55119,634,302 99.1%Elected—
(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 87,110,990566,323503,922 --0 99.4%Passed (calculated)—
(iii) Non-binding advisory vote on compensation of the Company's named executive officers. 63,041,9545,198,616306,363 --19,634,302 92%Passed (calculated)—
(iv) Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers. 77,265,10710,557,548358,580 --0 88%Passed (calculated)—
(vi) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. 51,379,95816,912,205254,770 --19,634,302 75%Passed (calculated)—
(vii) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals. 72,616,99415,306,292257,949 --0 83%Passed (calculated)—

Source: FATE THERAPEUTICS INC., Form 8-K, filed with the SEC on May 30, 2025 — read the filing on EDGAR.

How asset managers voted at the FATE THERAPEUTICS INC. 2024-2025 meeting

144 asset managers disclosed a vote on at least one FATE THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of FATE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Bahram Valamehr, Ph.D., M.B.A.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 67,859,201WITHHELD: 687,732
Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Dr. Bahram Valamehr

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bahram Valamehr, Ph.D., M.B.A.”): 67,859,201 for, 687,732 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,921,029 for, 35,418 withheld.

FOR
FOR: 21,921,029WITHHOLD: 35,418
Largest asset managers voting on “Election of Class III Directors: Dr. Bahram Valamehr” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
AIG/SunAmerica87,6680 00For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

Elect Director: Dr. Shefali Agarwal

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 65,856,345WITHHELD: 2,690,588
Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Dr. Shefali Agarwal

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dr. Shefali Agarwal”): 65,856,345 for, 2,690,588 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,377,121 for, 579,326 withheld.

FOR
FOR: 21,377,121WITHHOLD: 579,326
Largest asset managers voting on “Election of Class III Directors: Dr. Shefali Agarwal” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial249,6610 071,854Mixed
TIAA310,7980 00For
Voya00 0238,872Withhold
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable16,8150 0146,580Mixed
ETF Series Solutions131,8300 00For
AIG/SunAmerica87,6680 00For
Thrivent87,0280 00For
Invesco00 074,126Withhold
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

Elect Director: Matthew C. Abernethy, M.B.A.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 67,935,382WITHHELD: 611,551
Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Matthew C. Abernethy

FATE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Matthew C. Abernethy, M.B.A.”): 67,935,382 for, 611,551 withheld, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,921,029 for, 35,418 withheld.

FOR
FOR: 21,921,029WITHHOLD: 35,418
Largest asset managers voting on “Election of Class III Directors: Matthew C. Abernethy” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
AIG/SunAmerica87,6680 00For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

To approve the amendment of our amended and restated certificate of incorporation to increase the authorized number of…

No official matchCAPITAL STRUCTURE

99.6% of fund votes cast · no official result

FOR
Details: description as filed, votes by 45 asset managers

Description as filed by funds: TO APPROVE THE AMENDMENT OF OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK FROM 250,000,000 TO 350,000,000.

The 45 asset managers below reported 21,858,924 for, 84,518 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 21,858,924AGAINST: 84,518
Largest asset managers voting on “TO APPROVE THE AMENDMENT OF OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED N” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
AIG/SunAmerica87,6680 00For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM14,90049,100 00Mixed
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

(vii) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual…

Calculated outcomeCORPORATE GOVERNANCEPassed (calculated)

83% Majority: yes · of votes cast

FOR 83%AGAINST
FOR: 72,616,994AGAINST: 15,306,292
Details: description as filed, official tally, votes by 45 asset managers

Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE ANY OF THE ABOVE PROPOSALS.

FATE THERAPEUTICS INC.’s own tally for this item (“(vii) Approval of the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.”): 72,616,994 for, 15,306,292 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 45 asset managers below reported 19,114,551 for, 2,793,473 against, 35,418 abstained.

FOR
FOR: 19,114,551AGAINST: 2,793,473ABSTAIN: 35,418
Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEET” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional01,013,439 00Against
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle0411,154 00Against
Lincoln Financial243,47178,044 00Mixed
TIAA0310,798 00Against
Voya0238,872 00Against
Nationwide4,792203,417 00Against
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions0131,830 00Against
AIG/SunAmerica087,668 00Against
Thrivent087,028 00Against
Invesco74,1260 00For
Prudential/PGIM49,10014,900 00Mixed
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust038,377 00Against
John Hancock037,096 00Against

Showing the 25 largest of 45 asset managers. All 45 are in the interactive database (link above).

(vi) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock…

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 2 wordings of this item as funds reported it.

75% Majority: yes · of votes cast

FOR 75%AGAINST
FOR: 51,379,958AGAINST: 16,912,205
Details: description as filed, official tally, votes by 48 asset managers

Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.

FATE THERAPEUTICS INC.’s own tally for this item (“(vi) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 51,379,958 for, 16,912,205 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan01,190,231 00Against
Dimensional01,013,439 00Against
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle0411,154 00Against
Lincoln Financial0321,515 00Against
TIAA0310,798 00Against
Voya0238,872 00Against
Nationwide4,792203,417 00Against
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable16,815146,580 00Mixed
ETF Series Solutions0131,830 00Against
AIG/SunAmerica087,668 00Against
Thrivent087,028 00Against
Invesco074,126 00Against
Prudential/PGIM49,10014,900 00Mixed
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock037,096 00Against

Fund voting reports, all 46 managers: 17,498,099 for, 4,422,930 against, 35,418 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Integral Health Asset Management, LLC412,1030 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC0840 00Against

Institutional-manager reports, all 2 managers: 412,103 for, 840 against.

(iii) Non-binding advisory vote on compensation of the Company's named executive officers.

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 63,041,954AGAINST: 5,198,616

Prior year: 71.9% for (June 3, 2024 meeting) ▲ 20.5 pts

Details: description as filed, official tally, votes by 140 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.

FATE THERAPEUTICS INC.’s own tally for this item (“(iii) Non-binding advisory vote on compensation of the Company's named executive officers.”): 63,041,954 for, 5,198,616 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 45 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional01,013,439 00Against
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial315,3256,190 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide204,4293,780 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable16,815146,580 00Mixed
ETF Series Solutions131,8300 00For
AIG/SunAmerica87,6680 00For
Thrivent87,0280 00For
Invesco074,126 00Against
Prudential/PGIM064,000 00Against
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X059,861 00Against
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For

Fund voting reports, all 45 managers: 20,458,828 for, 1,449,196 against, 35,418 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 114 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as dis” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC12,872,9460 00For
Citadel3,273,6430 00For
BlackRock3,270,041812 00For
GEODE CAPITAL MANAGEMENT, LLC2,269,6090 00For
ORBIMED ADVISORS LLC01,680,580 00Against
JACOBS LEVY EQUITY MANAGEMENT, INC1,536,0860 00For
Woodline Partners LP1,370,1670 00For
Vestal Point Capital, LP1,056,6550 00For
State Street991,571638 00For
Goldman Sachs816,3080 00For
Charles Schwab703,8250 00For
Vanguard555,7840 00For
DE Shaw433,1920 00For
Integral Health Asset Management, LLC412,1030 00For
Northern Trust389,4420 00For
Nuveen378,3880 00For
Two Sigma344,8420 00For
MELLON INVESTMENTS Corp321,7310 00For
Voya238,8720 00For
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO163,0740 00For
AllianceBernstein0146,580 00Against
Invesco0140,248 00Against
Dimensional096,462 00Against
Thrivent89,3220 00For
Callan Family Office, LLC82,0240 00For

Institutional-manager reports, all 114 managers: 31,997,536 for, 2,481,953 against, 1,500 abstained, 39,105 1 year. Showing the 25 largest; every one is in the interactive database (link above).

(iv) Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 7 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%
FOR: 77,265,107AGAINST: 10,557,548
Details: description as filed, official tally, votes by 140 asset managers

Description as filed by funds: To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes to approve the compensation of the Company's named executive officers.

FATE THERAPEUTICS INC.’s own tally for this item (“(iv) Non-binding advisory vote on the frequency of future non-binding advisory votes to approve the compensation of the Company's named executive officers.”): 77,265,107 for, 10,557,548 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes ” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
BlackRock00 00--
Fidelity00 00--
JPMorgan00 00--
Dimensional00 00--
Charles Schwab00 00--
BRUCE FUND INC00 00--
Columbia Threadneedle00 00--
Lincoln Financial00 00--
TIAA00 00--
Voya00 00--
Nationwide00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
Equitable00 00--
ETF Series Solutions00 00--
AIG/SunAmerica00 00--
Thrivent00 00--
Invesco00 00--
Prudential/PGIM00 00--
MASTER INVESTMENT PORTFOLIO00 00--
Global X00 00--
Pacific Life00 00--
Bridge Builder Trust00 00--
Northern Trust00 00--
John Hancock00 00--

Fund voting reports, all 46 managers: 35,418 abstained, 20,865,507 1 year, 1,055,522 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 112 asset managers voting on “To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder advisory votes ” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Redmile Group, LLC00 00--
Citadel00 00--
BlackRock00 00--
JPMorgan00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
ORBIMED ADVISORS LLC00 00--
JACOBS LEVY EQUITY MANAGEMENT, INC00 00--
Woodline Partners LP00 00--
Vestal Point Capital, LP00 00--
State Street00 00--
Goldman Sachs00 00--
Charles Schwab00 00--
Vanguard00 00--
DE Shaw00 00--
Integral Health Asset Management, LLC412,1030 00For
Northern Trust00 00--
Nuveen00 00--
Two Sigma00 00--
MELLON INVESTMENTS Corp00 00--
Voya00 00--
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO00 00--
AllianceBernstein00 00--
Invesco00 00--
Dimensional00 00--
Thrivent00 00--

Institutional-manager reports, all 112 managers: 457,087 for, 1,058 against, 1,500 abstained, 37,051,792 1 year, 96,747 3 year. Showing the 25 largest; every one is in the interactive database (link above).

(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 87,110,990AGAINST: 566,323

Prior year: 99.9% for (June 3, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

FATE THERAPEUTICS INC.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 87,110,990 for, 566,323 against, per its Form 8-K filed May 30, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 21,920,608 for, 421 against, 35,418 abstained.

FOR
FOR: 21,920,608AGAINST: 421ABSTAIN: 35,418
Largest asset managers voting on “TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE C” at FATE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,783,1980 00For
BlackRock3,888,7390 00For
Fidelity2,013,6590 00For
JPMorgan1,190,2310 00For
Dimensional1,013,4390 00For
Charles Schwab703,8250 00For
BRUCE FUND INC550,0000 00For
Columbia Threadneedle411,1540 00For
Lincoln Financial321,5150 00For
TIAA310,7980 00For
Voya238,8720 00For
Nationwide208,2090 00For
QUANTITATIVE MASTER SERIES LLC177,4790 00For
Equitable163,3950 00For
ETF Series Solutions131,8300 00For
AIG/SunAmerica87,6680 00For
Thrivent87,0280 00For
Invesco74,1260 00For
Prudential/PGIM64,0000 00For
MASTER INVESTMENT PORTFOLIO60,1210 00For
Global X59,8610 00For
Pacific Life55,5870 00For
Bridge Builder Trust45,0980 00For
Northern Trust38,3770 00For
John Hancock37,0960 00For

Showing the 25 largest of 46 asset managers. All 46 are in the interactive database (link above).

Largest FATE THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 114,603,910 shares outstanding at the time of that meeting.

Fund voting reports: top FATE THERAPEUTICS INC. shareholders by shares voted on “To recommend, on a non-binding advisory basis, the frequency of future non-binding stockholder…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.54%
2BlackRock 3.39%
3Fidelity 1.76%
4JPMorgan 1.04%
5Dimensional 0.88%
6Charles Schwab 0.61%
7BRUCE FUND INC 0.48%
8Columbia Threadneedle 0.36%
9Lincoln Financial 0.28%
10TIAA 0.27%
Institutional-manager reports: top FATE THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Redmile Group, LLC 11.23%
2Citadel 2.86%
3BlackRock 2.85%
4GEODE CAPITAL MANAGEMENT, LLC 1.98%
5ORBIMED ADVISORS LLC 1.47%
6JACOBS LEVY EQUITY MANAGEMENT, INC 1.34%
7Woodline Partners LP 1.20%
8Vestal Point Capital, LP 0.92%
9State Street 0.87%
10Goldman Sachs 0.71%

Reported FATE THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

FATE THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Redmile Group, LLC18,229,078 15.91%Schedule 13D, filed April 22, 2026
Entities affiliated with Redmile Group, LLC12,872,946 11.23%Proxy statement (DEF 14A), table as of March 31, 2025
BlackRock10,681,779 9.32%Form 13F, quarter ended March 31, 2025
ARK Investment Management LLC10,312,167 9.00%Proxy statement (DEF 14A), table as of March 31, 2025
Vanguard Group10,310,453 9.00%Form 13F, quarter ended March 31, 2025
JPMorgan Chase3,398,283 2.97%Form 13F, quarter ended March 31, 2025
Dimensional Fund Advisors2,591,558 2.26%Form 13F, quarter ended March 31, 2025
Goldman Sachs2,458,974 2.15%Form 13F, quarter ended March 31, 2025
Geode Capital2,269,609 1.98%Form 13F, quarter ended March 31, 2025
Morgan Stanley2,240,058 1.95%Form 13F, quarter ended March 31, 2025

Percentages above are of 114,603,910 shares outstanding, as reported by FATE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At FATE THERAPEUTICS INC.'s shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 144 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,569 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: FATE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 30, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from FATE THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

FATE THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “FATE THERAPEUTICS (FATE) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/fate-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.